Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy

BACKGROUND: To mitigate the risk of stent thrombosis, patients treated by percutaneous coronary intervention (PCI) are administered dual anti-platelet therapy comprising aspirin and a platelet P2Y(12) receptor inhibitor. Clopidogrel is a prodrug requiring activation by the cytochrome P450 enzyme, CY...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Rubaish, Abdullah M., Al-Muhanna, Fahad A., Alshehri, Abdullah M., Al-Mansori, Mohammed A., Alali, Rudaynah A., Khalil, Rania M., Al Faraidy, Khalid A., Cyrus, Cyril, Sulieman, Mohammed M., Vatte, Chittibabu, Claassens, Daniel M. F., ten Berg, Jurriën M., Asselbergs, Folkert W., Al-Ali, Amein K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271437/
https://www.ncbi.nlm.nih.gov/pubmed/32493215
http://dx.doi.org/10.1186/s12872-020-01558-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271437/
https://www.ncbi.nlm.nih.gov/pubmed/32493215
http://dx.doi.org/10.1186/s12872-020-01558-2

Ejemplares similares